The company added that the results, issued today, Sunday, showed that the drug improved respiratory symptoms and fever caused by the disease.
She indicated that the drug was taken, during clinical trials, orally once a day for five days.
The company hopes that the experimental treatment, which is in the form of tablets, will achieve global spread after obtaining the approval of the regulatory authorities in Japan, which is currently examining it.
And “Shinoji” revealed, last March, that it would launch the third phase of clinical trials for the treatment globally, with the support of the US government.
“We look forward to continuing the study and testing of this antiviral drug in phase 3 trials,” said Isao Techirogyi, the company’s president and CEO.